Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 203 Redwood Shores Parkway, Suite 500 REDWOOD CITY CA 94065 |
Tel: | N/A |
Website: | https://soleno.life |
IR: | See website |
Key People | ||
Anish Bhatnagar President, Chief Executive Officer, Chief Operating Officer, Director | James H. Mackaness Chief Financial Officer | Lauren Budesheim Vice President - Human Resources |
Dairine Dempsey Vice President - Europe | Patricia C. Hirano Vice President - Regulatory Affairs | Kristen Yen Vice President - Clinical Operations | Meredith Manning Chief Commercial Officer |
Business Overview |
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR's mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union. |
Financial Overview |
For the fiscal year ended 31 December 2023, Soleno Therapeutics Inc revenues was not reported. Net loss increased 62% to $39M. Higher net loss reflects ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS segment loss increase of 70% to $41.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.87 to -$2.36. |
Employees: | 33 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,078M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$39.43M as of Dec 31, 2023 |
Net annual income (TTM): | -$38.99M as of Dec 31, 2023 |
Free cash flow (TTM): | -$24.94M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 33,411,329 as of Apr 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |